Date: July 21-23, 2021
Virtual Event
Companies and professionals from the biocompatibility, toxicology, materials engineering, and related medical fields are invited to attend the Q1 Productions’ 2nd Annual Medical Device Biocompatibility & Toxicology Risk Assessment Conference being held on July 21-23, 2021. Industry leaders and regulatory authorities will share presentations discussing compliant design and commercialization evaluation processes for medical device professionals to develop safe testing strategies.
This online streaming conference is a great opportunity for you to meet and collaborate with industry professionals to ensure your products meet biological safety requirements as per the global safety standards. The event will be hosted on the dynamic Q1 Productions virtual platform that customizes the user experience by connecting attendees with their peers. Attendees will get answers to their queries while the dynamic formats ensure that participants enjoy the virtual experience.
Industry leaders attending the conference will discuss safety measures and safety standards to meet the design requirements for the commercial market. The event is sponsored by WuXi AppTec Medical Device Testing, a world-class solution provider offering integrated, testing solutions that enable clients to develop strategies and safe life-changing healthcare solutions for patients and caregivers. The conference media partner is BioMedWire (“BMW”), a technology-driven communications platform.
Important points to be covered at the Conference:
- Designing proper biological evaluation plans in a risk management process
- Discussion on the criteria, selection, and common measures for risk-based biological evaluation planning
- Ways to refine E&L Testing performance and efficiency
- Overcoming biocompatibility and toxicology challenges of the world markets
- Partnering with lab-testing services for better navigation, communication and to overcome the lack of uniformity
- Defining testing criteria for ethylene oxide residual testing
- Optimizing biocompatibility analysis in response to manufacturing alterations
The 2nd Annual Medical Device Biocompatibility & Toxicology Risk assessment Conference offers insights and valuable information that allows you to test planning with in-depth analysis of regulatory requirements to ensure product reliability & patient safety.
Q1 productions have a Virtual Event Guide & FAQ forum for a better user experience. The mobile app Q1 Events offers all networking experiences of the virtual platform for a seamless experience.
For more information about the event, please visit https://ibn.fm/uRrPo.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.